Sus Scrofa Skin

Dosage for Sus Scrofa Skin is highly individualized and must be performed by a trained allergist or immunologist.

Skin Prick Testing (SPT)

For diagnostic purposes, a single drop of the Sus Scrofa Skin extract (typically 1:10 or 1:20 concentration) is applied to the volar surface of the forearm or the back. A sterile lancet is then used to prick the skin through the drop. The standard 'dose' is effectively the amount of protein that enters the epidermis during this procedure, which is estimated to be less than 0.001 mL.

Intradermal Testing

If the skin prick test is negative but clinical suspicion remains high, an intradermal injection may be performed. The typical dose is 0.02 to 0.05 mL of a 1:100 or 1:1000 dilution of the extract, injected to create a small bleb (2-3 mm) under the skin surface.

Sus Scrofa Skin extracts are used in pediatric populations for the diagnosis of food or animal allergies.

• Infants and Children: The procedure is identical to adult skin prick testing. However, the number of tests performed in a single session may be limited to minimize discomfort and the risk of a systemic reaction.
• Safety: Pediatric use must be supervised by a pediatric allergist. There is no established 'minimum age,' but skin reactivity may be lower in infants under 6 months of age, potentially leading to false-negative results.

Renal Impairment

No dosage adjustments are required for renal impairment, as the systemic exposure to Sus Scrofa Skin proteins during diagnostic testing is minimal. However, patients with end-stage renal disease may exhibit altered skin reactivity (uremic pruritus or decreased inflammatory response), which can complicate the interpretation of results.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver disease. The metabolic clearance of the minute amounts of protein used in testing does not rely on hepatic CYP450 pathways.

Elderly Patients

In patients over the age of 65, skin reactivity may be diminished due to age-related changes in the dermis and a decrease in mast cell density. Clinicians may need to use a positive control (histamine) to ensure the skin is capable of mounting a response before interpreting a negative Sus Scrofa Skin test.

Sus Scrofa Skin is not a medication that a patient 'takes' at home. It is a diagnostic or surgical biological administered exclusively by healthcare professionals.

• Preparation: Ensure the patient has avoided antihistamines for at least 48 to 72 hours prior to testing.
• Site Selection: The skin site must be clean and free of dermatitis or scarring.
• Observation: After the extract is applied, the patient must remain in the clinic for at least 30 minutes for observation of both local and systemic reactions.
• Storage: The liquid extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the allergenic proteins.

As this is a diagnostic procedure, a 'missed dose' simply refers to a cancelled or postponed appointment. There are no pharmacological consequences to missing a diagnostic test, other than a delay in identifying the cause of the patient's symptoms.

An 'overdose' of Sus Scrofa Skin extract typically occurs in the context of:

1. 1Testing too many allergens simultaneously (summation effect).
2. 2Using an intradermal concentration that is too high for a highly sensitized patient.

Symptoms of Overdose (Systemic Reaction):

• Generalized hives (urticaria)
• Swelling of the lips, tongue, or throat (angioedema)
• Wheezing or difficulty breathing
• Rapid drop in blood pressure (hypotension)

Emergency Measures:

In the event of an overdose or systemic reaction, the administration of intramuscular epinephrine (0.3 mg for adults) is the first-line treatment. Oxygen, intravenous fluids, and antihistamines may also be required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt self-testing without medical guidance.

The most frequent side effects associated with Sus Scrofa Skin are localized to the site of administration. These are often expected as part of the diagnostic process.

• Pruritus (Itching): Intense itching at the test site is the most common complaint. This typically begins within 5 minutes of application and subsides within 1-2 hours.
• Wheal Formation: A raised, pale bump (similar to a mosquito bite) at the site of the prick. This is the positive diagnostic marker.
• Erythema (Redness/Flare): A red, flushed area surrounding the wheal. This is caused by local vasodilation and can vary in size from 10 mm to over 50 mm.
• Local Tenderness: The site may feel slightly sore or warm to the touch for several hours following the test.

• Delayed Local Reaction: Some patients may experience a recurrence of swelling and redness at the test site 6 to 24 hours after the initial test. This is known as a 'late-phase reaction.'
• Lymphangitis: Very rarely, a red streak may develop extending from the test site, indicating temporary inflammation of the lymph vessels.
• Persistent Itching: In sensitive individuals, the itch may persist for 24-48 hours, requiring topical corticosteroid application.

• Vasovagal Reaction: Fainting or lightheadedness due to the stress of the needle prick or the sight of blood, rather than the extract itself.
• Subcutaneous Nodules: A small, firm lump may form at the site of an intradermal injection, which usually resolves within a week.
• Infection: As with any procedure that breaks the skin barrier, there is a remote risk of localized cellulitis (skin infection).

While rare during skin prick testing, systemic reactions can be life-threatening.

> Warning: Stop the procedure and call for emergency assistance immediately if you experience any of the following:

• Anaphylaxis: A severe, multi-system allergic reaction. This is the most critical risk of Sus Scrofa Skin exposure in highly sensitized individuals.
• Angioedema: Rapid swelling of the deep layers of the skin, particularly around the face, eyes, and throat, which can obstruct the airway.
• Bronchospasm: Sudden constriction of the muscles in the walls of the bronchioles, leading to severe wheezing and respiratory distress.
• Hypotension: A sudden, dangerous drop in blood pressure that may lead to dizziness, confusion, or loss of consciousness.
• Generalized Urticaria: Hives that spread far beyond the test site to cover large areas of the body.

There are no known long-term systemic side effects associated with the one-time diagnostic use of Sus Scrofa Skin. Because the substance is a natural protein extract, it does not accumulate in tissues or cause chronic organ toxicity. In the context of biological dressings, the material is designed to be incorporated into the healing tissue or naturally degraded.

FDA Black Box Warning for Allergenic Extracts:

Sus Scrofa Skin, as an allergenic extract, carries a standardized warning regarding the risk of severe non-fatal and fatal systemic reactions.

• Risk of Anaphylaxis: This product can cause anaphylaxis, which may be life-threatening.
• Clinical Setting: Extracts should only be administered by physicians who are exceptionally experienced in the treatment of systemic reactions and have immediate access to emergency medications, including epinephrine.
• Patient Monitoring: Patients must be observed for at least 30 minutes following administration to detect the early signs of a systemic reaction.
• Asthma Risk: Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions and should be evaluated carefully before testing.

Report any unusual symptoms to your healthcare provider immediately. If you have a history of severe reactions to pork or mammalian products, ensure your doctor is aware before testing begins.

Sus Scrofa Skin is a potent biological agent. Its use is strictly diagnostic or surgical and must never be attempted by the patient at home. The most significant safety concern is the potential for an unpredictable systemic allergic reaction. Patients must be transparent with their healthcare provider regarding their full allergy history, including any previous reactions to meat, gelatin, or vaccines (some of which contain porcine-derived stabilizers).

No specific 'individual' black box warning exists for Sus Scrofa Skin alone, but it falls under the General Black Box Warning for Allergenic Extracts. This warning emphasizes that these products are intended for use only by clinicians prepared to manage anaphylaxis. It notes that the risk is higher in patients receiving beta-blockers, as these medications can interfere with the effectiveness of epinephrine used in emergencies.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is an IgE-mediated systemic response. This is more common in patients with a history of high-titer sensitivity to mammalian proteins.
• Asthma Exacerbation: Patients with poorly controlled asthma should not undergo skin testing with Sus Scrofa Skin, as they are predisposed to more severe respiratory complications if a systemic reaction occurs.
• Beta-Blocker Therapy: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making the management of a potential allergic reaction much more difficult.
• Dermatographism: Patients with 'skin writing' (dermatographism) may produce false-positive results, as the simple act of pricking the skin causes a wheal, regardless of the extract used.

• Post-Test Observation: A mandatory 30-minute wait period in the clinic is required after administration.
• Baseline Vital Signs: For high-risk patients, baseline blood pressure and lung function (peak flow or spirometry) may be measured before testing.
• Skin Inspection: The test site must be monitored for excessive local reactions (greater than 10 cm) which may predict a higher risk for future systemic issues.

In the absence of a systemic reaction, Sus Scrofa Skin does not impair the ability to drive or operate machinery. However, if a patient experiences a vasovagal reaction (fainting) or is administered epinephrine/antihistamines for a reaction, they should not drive until fully recovered and cleared by a physician.

Alcohol consumption should be avoided for 24 hours before and after testing. Alcohol can increase peripheral vasodilation, which may potentially enhance the size of the skin reaction or increase the rate of systemic absorption of the allergen.

There is no 'discontinuation' or 'tapering' required for Sus Scrofa Skin, as it is not a chronic medication. If a patient experiences a severe reaction during a skin test, the procedure is immediately halted, and the extract is washed off the skin.

> Important: Discuss all your medical conditions, especially respiratory or cardiac issues, with your healthcare provider before starting Sus Scrofa Skin testing.

There are no drugs that are strictly 'contraindicated' in the sense of causing a toxic chemical reaction, but certain drugs make the use of Sus Scrofa Skin dangerously unsafe or clinically useless:

• Beta-Blockers (Systemic and Ophthalmic): Medications like propranolol or timolol eye drops are contraindicated during allergy testing because they block the receptors that epinephrine needs to act upon during an anaphylactic emergency. This can lead to treatment-resistant anaphylaxis.

• ACE Inhibitors: Drugs like lisinopril or enalapril can increase the risk of severe angioedema (swelling) during an allergic reaction and may worsen the severity of anaphylaxis.
• MAO Inhibitors: Monoamine oxidase inhibitors (e.g., phenelzine) can potentiate the effects of epinephrine, leading to a hypertensive crisis if epinephrine must be used to treat a reaction to the skin test.
• TCAs (Tricyclic Antidepressants): Similar to MAOIs, TCAs like amitriptyline can increase the cardiovascular response to epinephrine.

• Antihistamines (H1 Blockers): Drugs like cetirizine (Zyrtec), loratadine (Claritin), and diphenhydramine (Benadryl) will suppress the wheal-and-flare response. These MUST be discontinued 3 to 7 days before testing to avoid false-negative results.
• H2 Blockers: Medications like famotidine (Pepcid) can also slightly diminish the skin's allergic response and should ideally be stopped 48 hours before testing.
• Systemic Corticosteroids: Long-term use of prednisone can thin the skin and reduce the inflammatory response, potentially leading to inaccurate test results.

• Alpha-Gal Containing Foods: Consumption of pork, beef, or lamb shortly before testing may prime the immune system and potentially increase the risk of a more robust reaction to the Sus Scrofa Skin extract.
• High-Fat Meals: No direct interaction, but heavy meals may complicate the management of nausea or vomiting if a systemic reaction occurs.

• St. John's Wort: May theoretically interact with the metabolism of medications used to treat allergic reactions, though clinical data is limited.
• Licorice Root: Can affect cortisol levels and potentially interfere with the skin's inflammatory response.
• High-Dose Vitamin C: Some studies suggest very high doses of Vitamin C may have a mild antihistamine effect, which could theoretically dampen a skin test result.

• Serum Tryptase: If a systemic reaction occurs, a serum tryptase test may be drawn. The presence of Sus Scrofa Skin in the system does not 'interfere' with the test; rather, the reaction it causes will result in elevated tryptase levels, which is used to confirm anaphylaxis.
• IgE Testing: Sus Scrofa Skin testing does not interfere with in vitro (blood) IgE tests like ImmunoCAP, though both are used together to build a diagnostic picture.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, depression, or allergies.

Sus Scrofa Skin must NEVER be used in the following circumstances:

• Previous Severe Systemic Reaction: If a patient has a documented history of life-threatening anaphylaxis to Sus Scrofa Skin or porcine-derived products, further skin testing is generally contraindicated unless performed in a highly controlled 'graded challenge' environment.
• Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) of less than 70% of predicted values are at an unacceptably high risk for fatal bronchospasm during testing.
• Acute Dermographism: In this condition, any physical stimulus to the skin causes a hive. Testing is contraindicated because the results will be impossible to interpret (all tests will appear positive).
• Active Dermatitis at Test Site: Testing on skin affected by eczema, psoriasis, or infection is contraindicated as it may exacerbate the condition or lead to false-positive results.

Conditions requiring careful risk-benefit analysis include:

• Pregnancy: While not an absolute contraindication, allergy testing is usually postponed until after delivery to avoid the risk of anaphylaxis-induced fetal hypoxia.
• Beta-Blocker Use: If the patient cannot safely stop their beta-blocker, the clinician must weigh the diagnostic necessity against the risk of difficult-to-treat anaphylaxis.
• Recent Systemic Allergic Reaction: If the patient had a major allergic reaction to any substance within the last 4-6 weeks, skin testing should be delayed. The 'refractory period' following a major reaction can lead to false-negative skin tests.

Patients sensitive to Sus Scrofa Skin may also react to:

• Other Mammalian Epithelia: Cat, dog, horse, or cow dander/skin extracts.
• Porcine-Derived Medications: Heparin, porcine insulin, or certain pancreatic enzyme replacements.
• Gelatin: Many vaccines and capsules contain porcine gelatin, which may cause cross-reactions in porcine-allergic individuals.

> Important: Your healthcare provider will evaluate your complete medical history and current skin condition before prescribing or administering Sus Scrofa Skin.

Sus Scrofa Skin is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with porcine skin extracts.

• Risk Summary: The primary concern during pregnancy is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis). Anaphylaxis in a pregnant woman can cause a sudden drop in blood pressure, leading to placental hypoperfusion and fetal hypoxia (lack of oxygen to the baby).
• Clinical Recommendation: Most allergists recommend deferring diagnostic skin testing until the postpartum period unless the information is critical for immediate management.

It is not known whether the proteins in Sus Scrofa Skin extract are excreted in human milk. However, because the amount used in diagnostic testing is so small and the proteins are rapidly degraded, it is highly unlikely that any significant amount would reach the nursing infant. The risk to the infant is considered minimal, but the mother should be monitored for any systemic reactions that could interfere with her ability to breastfeed.

Sus Scrofa Skin is safe and effective for use in children when administered by a specialist.

• Approved Use: It is used to diagnose pork allergy and cat-pork syndrome in pediatric patients.
• Special Considerations: Children may have more reactive skin than adults, but the size of the 'positive' wheal is generally interpreted using the same criteria. The psychological stress of needle pricks should be managed with appropriate numbing creams (like EMLA) if necessary, though these must be used with caution as they can occasionally interfere with skin reactivity.

• Skin Reactivity: Patients over 65 often have thinner skin and reduced mast cell activity, which can lead to smaller wheal sizes. A negative result in an elderly patient must be interpreted with caution.
• Polypharmacy: Elderly patients are more likely to be on beta-blockers or ACE inhibitors, increasing the risk profile of the procedure.
• Co-morbidities: Existing cardiovascular disease in geriatric patients makes them less able to tolerate the physiological stress of a systemic allergic reaction.

No specific studies have been performed in patients with renal impairment. However, since the proteins are degraded locally and systemic exposure is minute, no dosage adjustment is required. Clinicians should be aware that uremia (buildup of toxins in the blood) in advanced kidney disease can cause generalized itching, which may complicate the reading of a skin test.

There are no known issues with using Sus Scrofa Skin in patients with liver disease. The metabolic pathway for these biological proteins does not involve the liver's detoxification enzymes.

> Important: Special populations require individualized medical assessment and a cautious approach to diagnostic testing.

At the molecular level, Sus Scrofa Skin extract contains a variety of porcine proteins, most notably Serum Albumin and Immunoglobulins, as well as structural proteins like Collagen.

1. 1Immunological Action: In sensitized individuals, the protein allergens in the extract bind to bivalent IgE molecules anchored to the FcεRI receptors on the surface of cutaneous mast cells. This binding causes the receptors to aggregate (cross-link), triggering an intracellular signaling cascade involving tyrosine kinases (like Syk). This leads to the rapid release of pre-formed mediators (histamine, proteases) and the de novo synthesis of lipid mediators (prostaglandins, leukotrienes).
2. 2Vascular Action: The released histamine binds to H1 receptors on local blood vessels, causing vasodilation (the flare) and increased capillary permeability (the wheal).

• Onset of Action: The immunological response begins almost immediately upon contact with the dermis.
• Peak Effect: The wheal-and-flare reaction typically reaches its maximum size between 15 and 20 minutes after administration.
• Duration: The visible reaction generally fades within 2 to 4 hours as the mediators are metabolized and the fluid is reabsorbed into the lymphatic system.
• Tolerance: Repeated skin testing at the same site over a short period can lead to 'tachyphylaxis' or local mast cell depletion, resulting in a diminished response.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Systemic) |

| Protein Binding | Local tissue binding is high |

| Half-life | 15-30 minutes (local protein degradation) |

| Tmax | 15-20 minutes (for skin reaction) |

| Metabolism | Local Proteolysis |

| Excretion | Not applicable for diagnostic doses |

• Composition: A complex aqueous-glycerinated extract of porcine dermal tissue.
• Molecular Weight: Ranges from 10 kDa to over 200 kDa (various proteins).
• Solubility: Soluble in water and saline solutions.
• pH: Typically adjusted to 6.0–8.0 to maintain protein stability and minimize skin irritation.

Sus Scrofa Skin is classified as a Non-Standardized Animal Skin Allergenic Extract. It is related to other mammalian extracts such as Bos taurus (Cow) and Equus caballus (Horse) skin extracts. Within the EPC (Established Pharmacologic Class) system, it is also categorized as an Amino Acid [EPC] when its constituent proteins are the focus of therapeutic use.